Zoetis Inc. (ZTS) Expected to Announce Earnings of $0.63 Per Share
Wall Street analysts expect Zoetis Inc. (NYSE:ZTS) to report $0.63 earnings per share (EPS) for the current quarter, according to Zacks. Four analysts have issued estimates for Zoetis’ earnings. The highest EPS estimate is $0.64 and the lowest is $0.62. Zoetis reported earnings of $0.52 per share in the same quarter last year, which indicates a positive year over year growth rate of 21.2%. The business is scheduled to report its next quarterly earnings report before the market opens on Thursday, November 2nd.
On average, analysts expect that Zoetis will report full-year earnings of $2.34 per share for the current financial year, with EPS estimates ranging from $2.30 to $2.37. For the next financial year, analysts expect that the business will post earnings of $2.69 per share, with EPS estimates ranging from $2.59 to $2.74. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Zoetis.
Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, meeting the consensus estimate of $0.53. The firm had revenue of $1.27 billion for the quarter, compared to analyst estimates of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period last year, the firm earned $0.49 EPS.
A number of research analysts have commented on ZTS shares. Zacks Investment Research cut shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Tuesday, July 4th. Hilliard Lyons started coverage on shares of Zoetis in a research report on Tuesday, June 20th. They set a “buy” rating and a $77.00 price target on the stock. Deutsche Bank AG reiterated a “buy” rating and set a $65.00 price target (up from $62.00) on shares of Zoetis in a research report on Monday, July 17th. Stifel Nicolaus reiterated a “buy” rating and set a $65.00 price target on shares of Zoetis in a research report on Friday, September 1st. Finally, Cantor Fitzgerald set a $75.00 price target on shares of Zoetis and gave the company a “buy” rating in a research report on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $65.76.
Institutional investors have recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. lifted its position in Zoetis by 16.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after buying an additional 230 shares during the period. Harfst & Associates Inc. lifted its position in Zoetis by 16.1% during the second quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock valued at $117,000 after buying an additional 260 shares during the period. Guardian Life Insurance Co. of America lifted its position in Zoetis by 0.7% during the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock valued at $102,000 after buying an additional 13 shares during the period. Almanack Investment Partners LLC. purchased a new position in Zoetis during the second quarter valued at $119,000. Finally, Point72 Asia Hong Kong Ltd purchased a new position in Zoetis during the first quarter valued at $111,000. 93.19% of the stock is owned by institutional investors and hedge funds.
Shares of Zoetis (ZTS) traded up 0.52% during midday trading on Tuesday, hitting $66.05. 161,673 shares of the company traded hands. The stock has a market capitalization of $32.31 billion, a PE ratio of 37.34 and a beta of 1.02. Zoetis has a 52 week low of $46.86 and a 52 week high of $66.05. The stock has a 50 day moving average of $63.94 and a 200-day moving average of $60.97.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Thursday, November 9th will be paid a $0.105 dividend. This represents a $0.42 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date of this dividend is Wednesday, November 8th. Zoetis’s payout ratio is 23.73%.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.